3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
7
Genitourinary
6
Head & Neck
3
Thoracic
2
Sarcoma
2
Lymphoid
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
CNS
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Interventions
Injections
98
pembrolizumab
90
Carboplatin
57
Paclitaxel
54
Cisplatin
52
Nivolumab
44
Docetaxel
43
Pemetrexed
42
Gemcitabine
37
atezolizumab
32
tislelizumab
29
Bevacizumab
29
toripalimab
23
Fluorouracil
23
Capecitabine
23
Irinotecan
22
Oxaliplatin
20
durvalumab
19
Ipilimumab
18
Leucovorin
17
Cetuximab
17
Rifampin
14
Itraconazole
14
olaparib
13
spartalizumab
12
Midazolam
12
Cyclophosphamide
12
trifluridine tipiracil drug combination
11
sintilimab
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
bempegaldesleukin
×
Other solid neoplasm
×
Clear all
NCT02869295
2021-07-29
NKTR-214
Nektar Therapeutics
Phase 1/2
Completed
28 enrolled
16 charts